HUTCHMEDは608Mに上海のシドミソンに45%を販売し,新型がんや免疫疾患の治療に資金を調達した. HUTCHMED sold a 45% stake in Shanghai Hutchison for $608M to fund new cancer and immunological disease treatments.

バイオ医薬品会社であるHUTCHMEDは,新しいがんと免疫疾患の治療の開発に注力するために,上海ハッチソン製薬の45%の株式を6億8000万ドルで売却しました. HUTCHMED, a biopharmaceutical company, sold a 45% stake in Shanghai Hutchison Pharmaceuticals for $608 million to focus on developing new cancer and immunological disease treatments. 会社は,今年初めて臨床試験を受ける予定の抗体型療法プログラムを推進するため,収益を活用する予定である. The company plans to use the proceeds to advance its antibody-targeted therapy programs, with the first expected to enter clinical trials this year. HUTCHMEDはSHP PL 株式の5%の利息を保管する. HUTCHMED will retain a 5% equity interest in SHPL post-divestment.